Summary Cyclic AMP binding proteins were measured in the primary tumour from 100 patients with non-disseminated breast cancer selected on the basis that sufficient tumour material was available for analysis. These measurements have been related to factors of established prognostic value and to the patients' disease-free interval 
Studies of rodent mammary carcinomas have suggested that levels of cyclic AMP binding proteins may differ in tumours according to their degree of autonomy and their growth status (Bodwin & Cho-Chung, 1978; Cho-Chung et al., 1981) . However, the corresponding information is not available in human tumours although we and others have shown that levels of cyclic AMP binding may help to define groups of breast cancers with differing likelihood of response to endocrine therapy (Kvinnsland et al., 1983; Watson et al., 1987) . The With regard to menopausal status, 21 patients were premenopausal, eight were perimenopausal and 71 were postmenopausal. No significant differences were detected between any of the sub-groups (data not shown).
Oestrogen receptors were detected in in 77 tumours and absent in the remaining 23. The median level of cyclic AMP binding proteins was significantly higher (P <0.05) in the ER -ve tumours compared with those with receptors ( Figure 2a ). Assays for progestogen receptors were performed in 78 tumours of which 33 were positive. No significant difference was found in levels of cyclic AMP binding protein between PgR + ve and PgR -ve tumours (Figure 2b) .
Levels of tumour cyclic AMP binding proteins subdivided according to tumour grade, the patient's histological lymph node status and clinical T stage are shown in Figure 3 . No significant differences between the sub-groups were detected. The group of grade 1 tumours had a lower median valuc than those of other grades but this was not statistically significant, perhaps because of the relatively small number of grade I tumours.
A minimum follow-up of 36 months was available on all patients. Levels of cyclic AMP binding proteins in tumours from patients who were either disease-free or had recurrent disease within 36 months are compared in associated with early recurrence (26 patients) was over 2-fold higher than that in tumours from the patients remaining disease-free (74). The difference in tumour cyclic AMP binding between these groups of patients was highly significant (P< 0.001).
In order to determine the value of tumour cyclic AMP binding which gave the maximum discrimination between tumours associated with early and non-recurrence, the data were retrospectively analysed by checking misclassification rates for a range of possible cut-off values. It was found that a value of 8 pmol mg-' cytosol protein minimised the percentage of patients misclassified at 16%. This value was subsequently used in a Cox analysis of disease-free interval (DFI) and survival data using the total follow-up data available on the patients (rather than performing analysis at 36 months).
Data on DFI are shown in Figure 5 Although we and others have indicated that the level of tumour cyclic AMP binding proteins may, in combination with ER, be helpful in predicting response to endocrine therapy in patients with advanced breast cancer (Kvinnsland et al., 1983; Watson et al., 1987) , we believe that the present paper is the first report that cyclic AMP binding proteins may be of prognostic value in patients with symptomatic breast cancer. Thus patients presenting with recurrent disease within 36 months of primary treatment had tumours with significantly higher levels of cyclic AMP binding protein than Table I Apart from the relationship with oestrogen receptors, no statistically significant correlation was detected between level of cyclic AMP binding proteins and other factors previously suggested to be of prognostic value, i.e. lymph node metastasis, tumour stage, grade and steroid receptor status. It would therefore seem that cyclic AMP binding proteins are independent of these parameters. That this is so is confirmed by multivariate analysis of the data, which shows that only cyclic AMP binding proteins and oestrogen receptor status were of significance in determining disease-free interval and only cyclic AMP binding proteins were statistically associated with overall survival. Other factors, such as lymph node involvement and T stage, showed a tendency to be associated with early recurrence but this did not reach statistical significance. Why these parameters, which in many studies are significantly associated with prognosis, were not more influential in the present group of patients is unclear. The data base does not represent a consecutive series of patients and constitues only 12% of those treated for operable breast cancer within one surgical unit. However, it is emphasised that no selection bias was applied apart from there being sufficient tumour for assay after material had been taken for histological diagnosis and measurement of oestrogen recep- tors. In general this meant that few clinical To and T, tumours were available for study.
Furthermore, although cyclic AMP binding proteins help to identify endocrine responsive tumours it seem unlikely that this is a factor contributing to the present findings. Cyclic AMP binding proteins were predictive of early recurrence irrespective of whether adjuvant endocrine treatment was administered.
It remains to be determined whether levels of cyclic AMP binding protein are simply markers of poor prognosis or are causally involved in aggressive tumour behaviour. There have been suggestions that during tumour growth, levels of cyclic AMP binding proteins are normally low but increase when cellular regression occurs (Bodwin & Cho-Chung, 1978) . A further hypothesis is that if, during active growth, cytoplasmic cyclic AMP binding protein levels are paradoxically high, control mechanisms have become defective and growth will be unregulated and unlikely to respond to normal restraints (Cho-Chung, 1980) . If this is the case, levels of cyclic AMP binding protein might not only reflect proliferation rates but also degree of autonomy.
Measurements of cyclic AMP binding proteins may therefore be useful in the management of patients with early breast cancer in terms of identifying those who have aggressive disease and would benefit from early intervention with adjuvant therapy. Assays of tumour cyclic AMP binding proteins are relatively easy to perform and do not require sophisticated methodology. Determinations are quantitative and our unpublished data indicate that valid results may be obtained from tumours stored in liquid N2 for up to 5 years. Only small amounts of material (100-200 mg) are required for assay, although tumour heterogeneity may dictate that representative samples are taken, particularly in large cancers (Senbanjo et al., 1986 ).
Finally it is emphasised that the present study has been based on retrospective analysis of a relatively small number of patients with comparatively short follow-up. It is felt, however, that the discriminating prognostic power of tumour cyclic AMP binding proteins shows sufficient promise to merit a prospective investigation.
